Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intelligent Bio Solutions (INBS) Current Deferred Revenue (2021 - 2025)

Intelligent Bio Solutions has reported Current Deferred Revenue over the past 4 years, most recently at $2.3 million for Q1 2024.

  • For Q1 2024, Current Deferred Revenue rose 109.36% year-over-year to $2.3 million; the TTM value through Mar 2024 reached $2.3 million, up 109.36%, while the annual FY2023 figure was $2.3 million, 17.57% down from the prior year.
  • Current Deferred Revenue for Q1 2024 was $2.3 million at Intelligent Bio Solutions, down from $2.4 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $4.7 million in Q2 2021 and troughed at $60413.0 in Q3 2022.
  • A 4-year average of $2.4 million and a median of $2.3 million in 2023 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 96.7% in 2022 and later skyrocketed 3609.35% in 2023.
  • Year by year, Current Deferred Revenue stood at $3.4 million in 2021, then tumbled by 37.08% to $2.2 million in 2022, then increased by 12.95% to $2.4 million in 2023, then fell by 5.89% to $2.3 million in 2024.
  • Business Quant data shows Current Deferred Revenue for INBS at $2.3 million in Q1 2024, $2.4 million in Q4 2023, and $2.2 million in Q3 2023.